A61L24/106

ONE COMPONENT FIBRIN GLUE COMPRISING A POLYMERIZATION INHIBITOR

Provided herein are stable liquid sealant formulations comprising fibrin monomers and a reversible fibrin polymerization blocking agent, methods of preparing and using the formulations.

Collagen gel formulations
20230001047 · 2023-01-05 ·

The present inventors have developed printable collagen bioinks using unmodified type I collagen with mechanical and structural properties that facilitate application to tissue in a structured form. In particular, the compositions of the present invention may be used to apply collagen gels to tissue (e.g. eye) using two- or three-dimensional (extrusion) bioprinting techniques.

FIBRINOGEN AND THROMBIN SOLUTIONS FOR A FIBRIN SEALANT AND FIBRIN SEALANT KIT

Disclosed are a fibrinogen solution and a thrombin solution. The fibrinogen solution comprises fibrinogen at a concentration of at least 40 mg/ml, factor XIII, pharmaceutically acceptable additives and water. The dynamic viscosity of the fibrinogen solution measured at 20° C. increases at most by 35% after storing the solution at 20° C. for 30 days. The thrombin solution comprises thrombin, pharmaceutically acceptable additives and water. The thrombin activity decreases at most by 15% after storing the solution at 25° C. for 14 days. Also disclosed is a fibrin sealant kit with a first container comprising the fibrinogen solution and a second container comprising the thrombin solution. Further, methods for preparing a fibrin sealant and methods for treating a wound are disclosed.

FLOWABLE FIBRINOGEN THROMBIN PASTE

Compositions comprised of: (i) a blend of fibrinogen, thrombin, wherein the blend is in the form of a plurality of particles, and (ii) a hydrophobic dispersant, wherein the composition is in the form of a paste at at-least one temperature in the range of 10° C., to 37° C., are disclosed herein. Methods for preparing a fibrin adhesive sealant in/on an injured tissue are further disclosed.

SYSTEMS AND METHODS TO ENABLE PYLORIC CLOSURE

Devices, systems, and methods described herein relate to affecting an internal diameter of a body lumen, and, in many examples, of a pylorus. A silk-based bulking agent may be injected in a pyloric tissue so as to reduce an effective inner diameter of the pylorus. A multi-part occluding agent may be injected into a pylorus on the surface of the pyloric tissue to occlude the pylorus alone or in combination with the silk-based bulking agent.

Kit for Composition for Tissue Tract Sealing

The present invention provides a kit for preparing a composition for sealing a lung tract, comprising: (a) a first component comprising: (i) a fibrinogen solution, and (ii) prewet gelatin particles in an aqueous solution; and (b) a second component comprising: (i) a thrombin solution, and (ii) a dry gelatin powder; wherein the first and second components are stored separately and configured for mixing together to form a composition that is flowable and cross-linkable. The composition may be used to seal tissue tracts such as lung tissue tracts.

Use of adipose tissue-derived stromal stem cells in treating fistula

Provided herein are novel methods and composition utilizing adipose tissue-derived stromal stem cells for treating fistulae.

Use of photosynthetic scaffolds in tissue engineering

The present invention is concerned with a photosynthetic scaffold that delivers oxygen and its uses for tissue engineering and the treatment of ischemia.

FIBRINOGEN COMPRISING FORMULATION AND USES THEREOF
20230190993 · 2023-06-22 ·

The invention relates to compositions comprised of albumin and clottable proteins including fibrinogen and to use thereof e.g., for treating bleeding. In particular, the compositions are comprised of albumin and one or more clottable proteins, wherein the albumin and the one or more clottable proteins are present at a total concentration of at least 90% by total protein weight, wherein the clottable protein fibronectin is present at an amount of less than about 0.5% by total protein weight or is absent, and wherein the weight ratio of the albumin to the clottable protein fibrinogen is at least 1:15, respectively.